Today, Tengasco, the independent oil and gas developer which has made quite a name for itself in the Central Kansas Uplift by employing advanced analytical, developmental, and production technologies, reported 2011 drilling results (period ending Dec. 31), updating reserves and offering a portrait of its logistical operations.

CEO of TGC, Jeff Bailey, was keen to point out the all-time annual company record set for gross production of some 246k barrels in 2011, which eclipsed previous records set in 2008 (238k barrels). Explaining that this feat was not attributable to any periodic records being set (daily, monthly, etc. as those records were all set in 2008), Bailey detailed how TGC was able to bring the reserve replacement percentage up to 137% via generic drilling, as reserve additions outpaced production declines. Reserves have been increased without additional acquisitions and drilling expenses were paid for largely from additional cash flow attributable to rising oil prices.

TGC looks forward to a 10-K filing for FY11 (ending Dec 31) and intends to issue a press release on earnings at the same time, offering a March 30 deadline for the release.

A technology portfolio that ranges from microseismic interpretation-driven 3D seismic imaging to state-of-the-art polymer techniques for increasing production/reserves, while lowering the cost/water requirements and improving overall long-term performance, has made TGC a force to be reckoned with. Of 26 wells drilled in 2011, 16 have come through as producers and 10 were dry holes. Polymer activities have been extremely helpful, delimiting backflow water volume and creating a physical barrier whose fluid dynamics enable increased access for the oil to enter the tubing.

TGC has obtained ($1.7M) requisite casing, tubing, and pump jacks already this year for use on the first 20 of 36 wells to be drilled in 2012, positioning for an aggressive program to be approached via cash flow and minimal use of the borrowing base (no third party drilling partners to be used). A dedicated rig has been contracted for the year with an option to add additional rigs should activity demand it, and the 2012 drilling program, while emphasizing Kansas operations, will also be going after targets on property in Tennessee (where TGC is also headquartered). TGC has already knocked out the first three wells (drilled/completed) in the program in Kansas and begun the fourth, with solid anticipation of the ability to secure a second rig to accelerate the process.

Wholly-owned TGC subsidiary Manufactured Methane Corp. (MMC) began selling electricity generated at its Carter Valley methane extraction site (reported Jan 25, sold under contract through the Tennessee Valley Authority Generation Partners program and including local distributor Holston Electric Cooperative, Inc.). MMC is thus able to gain an additional revenue stream while offsetting facility energy costs as methane production continues alongside electric generation. The added benefit of reduced oxygen input, combined with upgrades in the collection system, have yielded exceptional in-service time since Jan 25 for the facility as well.

Bailey pointed to the ability to simultaneously add reserve growth and gear up for an aggressive 2012 drilling schedule/budget as indicators of the health of TGC, offering the analysis that these 2011 results show a real comeback for the company, after doing no drilling in 2009 and being limited by cash availability in 2010. Bailey cited the benefit to investors of the 36-well drilling program for 2012 being all company-owned wells and shareholders should be very pleased with the upcoming 10-K and financials.

Ongoing tensions over Iran have already pushed some analysts to view this game of brinkmanship as potentially pushing prices at the pump in Europe 25% higher as soon as April, thanks to Iran freezing deliveries (and subsequently setting conditions on future oil sales) to British/French companies amid essentially stalled negotiations and tightening sanction talk. This is an unmistakable gesture from the market for domestic energy producers.

For more information, or to stay up to date with the latest developments at Tengasco, Inc., please visit the company’s website at: www.Tengasco.com

Let us hear your thoughts below:

North Springs Resources Corp. is an exploration company focused on discovering and developing precious metal properties in Nevada, Arizona, and Mexico. The company continues to look for opportunities to add to its asset property base by acquiring additional leases or entering into joint ventures and partnerships that will add to shareholder value.

The company announced today that it has signed a definitive agreement with Hyperion Management Mining to acquire a 10% interest in an option on various gold and silver producing properties in Chihuahua, Mexico. In total the various properties have an inferred reserve estimate of 730,000 ounces of gold and 94 million ounces of silver.

Previously, this deal was also to include a 10% interest in a new milling facility to be built in the area. Both parties remain committed to this goal, but for now, will revisit the building of a milling facility at a later date. The company and its partners have also agreed to terminate the agreements for North Spring to acquire properties in Guyana due to local laws and regulations delaying plans for development of the properties.

Although a definitive agreement has been signed, closing of the deal is still subject to further due diligence, including an additional company-initiated review conducted by an independent, qualified, and licensed Mexican geologist to evaluate the properties in question. If all is well, the transaction is expected to proceed within 3-5 business days.

For further information about North Springs Resources, please visit the company’s website at www.northspringsresources.com

Let us hear your thoughts below:

InVivo Therapeutics Holdings Corp., focused on polymer technology to develop treatments to improve function in individuals with spinal cord injury, today announced former Stryker biomaterials product development specialist Brian Hess as its director of product development.

In the role of director, Hess is responsible for the management, development, and maintenance of InVivo’s pipeline and portfolio of products. Hess will head the effort to transition InVivo technologies from research and development through clinical trials and into production manufacturing by developing specifications, protocols, and reports.

Hess’ most previous role was his eight-year tenure with Stryker, where he developed biomaterial technologies for the orthopedic market. He has led multiple product development teams through the FDA process, and was instrumental in developing HydroSetTM, an injectable calcium phosphate based bone substitute, from concept to product launch. HydroSet has become the market-leading bone scaffold, and in recognition of his success, Stryker awarded Hess and his team with “Best Technology” and “Best Team Synergy.”

Hess’ resume also includes the achievement of being named “Co-Innovator of the Year” in 2010 at Stryker for his work on a novel bone adhesive technology. Hess and his team spent the past three years demonstrating the technology’s feasibility and safety, growing his team to more than 25 engineers and scientists.

“We believe Brian’s past successes in the medical device industry will lead the commercialization of the three products we intend to have under review at FDA this year, as well as help to bring our portfolio of products for other neurological conditions successfully to the market in the coming years,” InVivo CEO Frank Reynolds stated in the press release.

For more information visit www.invivotherapeutics.com

Let us hear your thoughts below:

Inovio Pharmaceuticals Inc., engaged in the development of vaccines for the treatment of cancers and infectious diseases, today announced that its next-generation surface skin electroporation technology was successfully used to significantly enhance the delivery of small interfering RNA (siRNA) molecules to skin in animal studies. While the company has several ongoing human trials demonstrating the efficacy of its electroporation technology, this study marks the first time that this technology has been applied to the delivery of siRNA molecules.

Both preclinical and clinical studies have demonstrated electroporation as an effective physical delivery method with the capability to improve the expression and immunogenicity of DNA vaccines by up to 100-fold.

Inovio said the positive outcome of this study emphasizes the “far-reaching therapeutic potential” for the company’s electroporation technology.

“Perhaps the biggest hurdle in realizing the full potential of RNA-based therapies is the lack of proper and efficient delivery of siRNA molecules. This study supports the idea that Inovio’s proprietary electroporation technology can successfully deliver breakthrough RNA therapies with the same efficacy and safety in which we deliver DNA therapies,” Dr. J. Joseph Kim, president and CEO of Inovio, stated in the press release. “Most important, our delivery platform could pave the way for the development of targeted RNA-based therapies for diseases and conditions that are now considered untreatable.”

Inovio noted that in recent studies, siRNAs have demonstrated potential as novel therapeutics due to their ability to induce robust, sequence specific gene silencing in cells. The method of utilizing siRNA to induce RNA interference (RNAi) has potential as a therapeutic approach to treat many currently untreatable disorders, such as some cancers and many viral and genetic diseases.

Data from today’s announced study was published in the journal Molecular Therapy – Nucleic Acids in a paper titled, “Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation.”

For more information visit www.inovio.com

Let us hear your thoughts below:

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

One of our most popular ways, the QualityStocks Blog, keeps investors up to date on everything related to the Small-Cap and Micro-Cap markets. Alternative fuels and power sources, entertainment media, telecommunications, delivery services, healthcare, and retail are all covered on a regular basis. By visiting our blog, investors discover emerging companies that they otherwise would not have heard about.

To visit our blog, please click the following link www.blog.qualitystocks.net

If you’d like to subscribe via an RSS reader, here’s our feed URL: http://blog.qualitystocks.net/?feed=rss2

Let us hear your thoughts below:

Located in Ft. Worth, Texas, VHGI Holdings is a diverse company focused on opportunities within the healthcare technology industry and other endeavors. VHGI Coal, a subsidiary of VHGI Holdings, is a rising star in the coal mining industry. Today, the young company took a major step towards prominence with the announcement they have completed the acquisition of Lily Group Inc. and cored $13,000,000 debt financing.

Leading the way at VGHI Holdings is Doug Martin whom serves as the company’s CEO. In reference to this press release, Martin stated, “This is an important step in the development of our business plan. Our initial goal was to complete this transaction in our Q1 of 2012, which we have accomplished. Our next goal is to close additional debt financings for Lily Group in order to pay-off certain indebtedness, exploit current mining operations and possibly acquire other coal mining opportunities.”

Lily Group President Rick Risinger added, “This is exactly why we chose Mr. Martin and VHGI Coal to be our partners. They have the financial expertise and wherewithal to bring what we needed to develop our mine. We look forward to exploiting our opportunities at the Landree Mine, as well as other coal mining opportunities.”

Currently, VHGI Holdings in trading in the $0.70 range. To learn more about this story or the company as a whole, visit their corporate website at www.vhgiholdings.com

Let us hear your thoughts below:

Socket Mobile, Inc. recently announced the upcoming debut of the Socket Bluetooth® Cordless Hand Scanner (CHS) 7Ci, a low-cost barcode scanner for the Apple iPad, iPhone, and iPod touch. The CHS 7Ci provides an affordable option for reading 1D barcodes using Apple devices.

Expanding upon Socket Mobile’s popular CHS Series 7 line, the Socket CHS 7Ci is a 1D imager-based barcode reader that can decode printed barcodes and barcodes displayed on device screens. It even features a special authentication chip to enable two-way communications with Apple devices, making SDK support for Apple iOS possible. The CHS 7Ci is also compatible with Android, BlackBerry, and Windows operating systems.

Lasse Styner Rostock, CEO of nSales, a mobile software developer that has deployed iOS applications with a 2D version of the CHS, remarked, “For sales force automation or field service, most of our customers only need to scan 1D barcodes. We welcome the new Socket CHS 7Ci as an economical option that will enable more of our customers to optimize their deployment of our iPad applications with high-performance barcode scanning.”

“Apple developers need a barcode scanner that supports two-way communications with iOS devices in order to enable data parsing, binary data, and other advanced features in their applications,” said Mike Gifford, executive vice president at Socket Mobile. “With the new Socket CHS 7Ci barcode scanner and our updated SocketScan 10 Software Development Kit, Apple developers can better target the vast majority of business barcode applications, which only involve 1D barcodes, while also offering a lower cost solution.”

Let us hear your thoughts below:

MZ Group (MZ), the world’s largest independent investor relations and corporate communications firm, announced that the MZ North America group has entered a strategic alliance with The DreamTeam Group (DTG), an independent social media relations and web-based marketing services firm. Together the two companies will enable publicly traded companies to reach institutional, high net worth, and retail investors via a complete suite of investor relations services that incorporates both traditional and non-traditional communication strategies.

“We see terrific collaboration opportunities with DTG,” stated Ted Haberfield, President of MZ North America. “The vast majority of our small-cap and micro-cap clients lack the expertise and resources needed to create and maintain an effective social media strategy. We can leverage DTG’s team of social media experts to quickly customize a comprehensive plan that complements MZ’s efforts in corporate branding and investor relations.”

“Social media has become a mandatory component of every public company’s corporate and investor communications program,” commented Michael McCarthy, Managing Director of The DreamTeam Group. “With extensive experience developing and executing integrated social media plans for private and public companies across a variety of industries, we offer a proven, turnkey set of solutions for MZ’s clients. Our joint efforts will result in greater awareness, more direct investor engagement and a stronger corporate brand, all of which will ultimately lead to a larger and more diverse shareholder base for these client companies.”

Let us hear your thoughts below:

ImmunoCellular Therapeutics, a clinical-stage company developing immune-based therapies for the treatment of brain and other cancers, today announced it has entered into an agreement with the University of Pennsylvania, under which ImmunoCellular is granted exclusive worldwide licensing for a patent pending technology for the production of high-activity dendritic cells (DCs).

ImmunoCellular said the licensed technology underlies its lead DC-based cancer vaccine candidate, ICT-107, for the treatment of glioblastoma multiforme. The license covers the application of the technology toward the development of therapeutics for all indications, excluding cancer and ductal carcinoma in situ.

The agreement enhances the value of ImmunoCellular’s intellectual property related to ICT-107, and as stated by Manish Singh, Ph.D., ImmunoCellular’s president and CEO, positions the company to reduce manufacturing costs associated with the vaccine.

“This licensing agreement represents an expansion of our intellectual property surrounding the technology underlying our lead product candidate, ICT-107. In addition to contributing to the powerful immune responses to ICT-107 we have observed to date, this technology also enables the manufacture of multiple vaccine shots from a single production run, allowing us to significantly reduce the cost of manufacturing the vaccine. As we continue advancing our ongoing phase II trial in glioblastoma, we are confident that will continue to realize the benefits of the enhanced efficacy and efficiency of this innovative dendritic-cell production method,” Dr. Singh stated in the press release.

The technology was developed by Brian J. Czerniecki, M.D., Ph.D., co-director of University of Pennsylvania’s Rena Rowan Breast Cancer Center and surgical director of the immunotherapy program at the Abramson Cancer Center.

To learn more about IMUC, please visit www.imuc.com

Let us hear your thoughts below:

A123 Systems, a leading developer and manufacturer of advanced lithium-ion batteries and energy storage systems for transportation, electric grid, and commercial applications, today introduced its Military 6T Battery, engineered specifically for military vehicle applications.

The new battery system was developed to replace the 6T lead acid batteries currently deployed in military vehicles. A123 says the Military 6T Battery features a longer-lasting, lighter-weight system for engine start and enabling longer-duration silent watch functionality.

“There are nearly 800,000 6T batteries currently deployed in U.S. military vehicles, and in 2010 alone, the military purchased about 300,000 6T batteries. Virtually all of these are lead acid, so we believe this creates a significant opportunity for our lighter-weight, longer-lasting, higher-performance lithium iron phosphate Military 6T Battery,” Les Alexander, general manager for the Government Solutions Group at A123 stated in the press release.

The Military 6T Battery is based on A123′s proprietary Nanophosphate® lithium iron phosphate technology. The Military 6T Battery leverages the systems engineering and manufacturing design utilized to produce A123′s 12V Engine Start Battery, which is currently offered to commercial automakers.

The company’s battery products offer longer life cycle compared to other battery technologies; are capable of rapid charging and powerful delivery; are 50 percent lighter than lead acid battery systems, which improves fuel economy for transport vehicles on the battlefield; and are equipped with battery management electronics to help balance and safeguard the cells.

“Our new solution has successfully demonstrated the ability to start a High-Mobility Multipurpose Wheeled Vehicle (HMMWV), and we have begun delivering 6T systems to a number of defense contractors so they can evaluate its performance as a first step toward potential high-volume production. We believe we can leverage our expertise in developing industry-leading products for commercial markets as well as our vertically integrated manufacturing capabilities to deliver systems that will complement the DoD’s strategy for deploying more energy-efficient technologies,” Alexander stated.

A123 will showcase the Military 6T Battery and its other government and military at the Association of the United States Army (AUSA) Winter Symposium, Feb. 22-24, 2012, in Fort Lauderdale, Fla.

For more information visit www.a123systems.com

Let us hear your thoughts below:

The SEC’s Office of Investor Education and Advocacy has put together a valuable online report to help protect investors from fraudulent investment schemes that make use of social media and other Internet based communications.

Today, investors, as well as businesses, routinely turn to the Web as a primary means of investment related communication, with a special focus on email and social media sites such as Facebook, YouTube, Twitter, and LinkedIn. However, although such technology can be a valuable investor tool, it can also be used for purposes of investment fraud. The ease with which impressive presentations and websites can be created, and millions of potential investors reached, makes it imperative that investors take extra care to verify everything they see or hear on the Internet.

The SEC wants investors to know that the key to avoiding investment fraud on the Internet is to be an educated investor. Here are a few simple steps to avoid getting caught in an investment scheme:

• Be Wary Of Unsolicited Offers To Invest – Social media sites, chat rooms, and bulletin boards can provide an easy way for investment fraud perpetrators to reach victims. Unsolicited investment related communications, such as a new post on your wall, a tweet mentioning you, a direct message, or an e-mail, could represent a fraudulent investment scheme. Unsolicited emails promoting a stock, even if it looks like it came from a personal friend, can in fact be a sign of an investment scheme.

• Be Wary Of Promotions That Sound Too Good To Be True – Any investment promotion that promises unusually high returns should be considered a red flag. Look out for phrases such as “incredible gains,” “breakout stock pick,” “almost no risk,” or any suggestion of guaranteed returns.

• Be Wary Of Affinity Fraud – Avoid making an investment decision based solely upon a recommendation of a member of an organization or online group to which you belong. Fraudsters know that people are more likely to trust fellow members, and can use this as a way to mislead. Even if you feel you know the person, always check out everything independently.

• Be Wary Of Time Pressures – Be careful of promotions that push for a quick decision, precluding any chance of thorough research.

• Be Wary Of Special Information – Watch out for promotions that are based upon any kind of “inside” or “confidential” information.

In addition to being on guard for the above mentioned red flags, learn to be careful when it comes to privacy and security settings. Unprotected information can be used by fraudsters in a variety of ways.

Most importantly, do your own research. Never simply accept the opinions of someone else, whether from an email, a social media site, a newsletter, a press release, or even a friend.

For additional information, visit www.sec.gov/investor/alerts/socialmediaandfraud.pdf

Let us hear your thoughts below:

To assist investors interested in the unique but challenging market of microcap stocks, the U.S. Securities and Exchange Commission (SEC) has created a useful guide, describing the special characteristics of microcap stocks, how to evaluate them, and what to watch out for. It also provides a number of handy links to additional information resources.

Below is just some of the information included in the SEC guide to microcaps:

• What Is a Microcap Stock?

The term Microcap Stocks applies to stocks of companies with very low capitalization, meaning the total value of the company’s stock. Such companies may have under a million dollars in net tangible assets.

• Where Do Microcap Stocks Trade?

Many microcap stocks trade in the “over-the-counter” (OTC) market and are quoted on OTC systems, such as the OTC Bulletin Board (OTCBB) or the “Pink Sheets.”

• How Are Microcap Stocks Different Than Other Stocks?

A lack of readily available and dependable information is the biggest difference between microcap and other stocks. In addition, there are no minimum standards for listing a microcap stock, such as a minimum amount of assets or minimum number of shareholders. And, since microcap companies are often small, relatively new, and have low trading volumes, microcap stocks typically involve more volatility and risk.

• Do Microcap Companies File Reports With The SEC?

All but the smallest companies are required to file reports with the SEC. Companies with less than $10 million in assets are generally not required to file with the SEC. Nevertheless, some smaller companies, including microcap companies, may choose voluntarily to register their securities with the SEC. Companies that register with the SEC must file quarterly, annual, and other reports. The more accurate information you can get about a company and its financial status, the less likely the chance of mistakes or fraud.

• What About Other Sources Of Information?

Although the SEC has no way of guaranteeing that a company is filing 100% truthful reports, by law the public reports that companies file with the SEC are expected to be truthful and complete. Such public information is an important resource for investors. There are many other sources of information on microcap and other stocks, but investors need to be wary of non-verifiable information that may be fraudulent. Fraudsters can distribute email spam, spreading false information to thousands of potential investors. Fraudsters can post messages on bulletin boards and chat rooms urging investors to buy microcap stocks based upon “inside” information. Microcap companies may pay stock promoters to recommend the stock in supposedly independent and unbiased investment newsletters even though such payments are not disclosed. Stock telemarketing companies can telephone potential investors to promote a stock which the investor may not realize the company has a direct financial interest in. Fraudsters can publish dishonest press releases with false or misleading information. In short, you have to make sure who you’re dealing with.

• What Are Good Sources Of Information On Microcap Companies?

Check with the company, or call your state securities regulator to see if the company is registered with the SEC. You can also check the SEC’s EDGAR database or their Public Reference Room to get information. The SEC guide provides a number of links to get the information you need.

For additional information, visit www.sec.gov/investor/pubs/microcapstock.htm

Let us hear your thoughts below:

Today before the opening bell, GlobalWise Investments, Inc. and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, provided an overview of the company’s new management team. The diverse roster of highly experienced professionals contribute a combined total of more than 150 years in ECM industry experience.

William J. “BJ” Santiago, President and CEO. BJ has more than 20 years of senior executive-level management experience with an emphasis in sales, operations and M&A activities in the public and private sectors. During his previous tenure at Lexmark, BJ was hand selected in 2008 by the Lexmark CEO to launch and lead all operations for the newly formed Content Management Sales Practices for North America, which was using the Intellinetics platform. Through this business venture, Intellinetics recognized his ability as an ECM industry thought leader. From here, he became a natural catalyst for Intellinetics’ business development and strategy. BJ also served eight years as a United States Army Infantry Officer and is a veteran of Operation Desert Storm.

Matthew Chretien, EVP and Chief Technology Officer. Matthew is a co-founder of Intellinetics and a strategic entrepreneur backed by more than 20 years of experience in technology sales, consulting and software product life cycle management within the aerospace, public safety, government and select commercial markets. After graduating from The Ohio State University with an engineering degree in 1990, he spent two years in the Fisher College of Business Doctoral Program at Ohio State in computer science to work on his Ph.D. During this period, Matthew discovered his research would be far too narrow to satisfy his interests and ultimately co-founded Intellinetics in 1994.

Michael Chretien, VP and Corporate Counsel. Michael is a co-founder of Intellinetics. After graduating from the University of Massachusetts with a Bachelor of Arts in economics in 1961, he joined the United States Marine Corps and retired in 1965 as a 1st Lieutenant. Michael continued to serve his country for 26 years in law enforcement and foreign counter intelligence. After retirement from government service, he continued his career in the law enforcement field by studying for his Juris Doctorate and was awarded a law degree from Capital University Law School in 1991. Michael’s next move was founding Intellinetics with his son Matthew using his law enforcement background as a client resource to consult and assist with document storage and various other IT-related solutions.

Thomas D. Moss, Chief Software Engineer. Tom is a co-founder of Intellinetics and director of the company’s software research and development efforts. He boasts 20 years of expertise in database application design and document imaging software technologies, and has earned both a mathematics degree and a computer science degree at the University of Wisconsin.

Michael A. Beck, Director of Operations. Mike brings to Intellinetics 17 years of IT experience, including IT management, hands on technical experience, departmental management, staff development, budget development and management, network design, large-scale project management, creation of a new IT telecommunications department, contract negotiations, vendor management and technology migrations. Mike has proven his ability to consistently bring projects in on time and within budget.

Neil C. Campbell, Director of Software Products Group. Neil has 16 years of experience in the IT field with an emphasis in infrastructure design, software architecture and productivity improvement solutions. Neil spent 11 years at Abbott Laboratories with focus on manufacturing IT operations and warehouse management systems before he joined Intellinetics as a project manager in fall of 2006. Neil was promoted to Director of Software products in 2008, where he currently contributes visionary leadership, thoughtful interpretation, diagnosis and resolution to complex business issues facing companies today and in the future. Neil holds a bachelor’s degree from The Ohio University and industry certifications from Microsoft, Cisco, Extreme Networks, HP, Dell, Marathon Technologies and IBM.

Jim Perry, Director of Business Development. Jim has more than 15 years of executive sales and marketing experience providing Electronic Content Management (ECM), workflow and advanced data capture solutions to the healthcare, government and insurance markets. Jim previously served as a Senior Account Executive for ImageSoft, Inc. where he was responsible for developing and selling ECM solutions to the healthcare, government, manufacturing and insurance markets. Jim was personally responsible for innovating and developing a marketing plan for the healthcare vertical market that resulted in ImageSoft being recognized in 2008 as No. 1 of more than 200 reseller integrators of OnBase ECM Software in the United States.

Robert Simmons, Director of Business Development. Robert’s experience in the print and imaging industry spans 15 years. He most recently served as the Director of Enterprise Solution Architecture for Samsung Electronics. Robert has been responsible for creating programs and services that analyze vertical market requirements for document and output solutions, which have resulted in millions of dollars in cost savings and efficiency gains. He has specialized in developing programs and solutions for healthcare, government and education customers in North America. Robert holds a bachelor’s degree in psychology from Lee University and an MBA from the University of Phoenix.

Randy Love, Director of Business Development. Over the past 10 years of his 25-year IT career, Randy’s efforts have been focused on the ECM market. Most recently he worked 4 years as the VP of Sales and Business Development at an Ohio based ECM provider counting a number of complex, multi-million dollar imaging solutions to his team’s credit. He also spent 4 years as a Government Industry Manager at Hyland Software where he was credited with assisting partners on numerous high profile public sector projects as well as leading direct efforts on a statewide SAP integration deal. Prior to focusing on the ECM industry, Randy spent five years marketing mobile data software solutions to criminal justice agencies and 10 years in the commercial sector with a national systems integration firm. Early in his career, Randy worked as a Systems Engineer and Programmer Analyst, which has transcended to the technical aptitude he brings to his current position. He is a Certified Document Imaging Architect (CDIA+), AIIM ECM Practitioner and computer science graduate with a Bachelor of Science from Youngstown State University.

Bob Peterson, Director of Business Development. Bob has over 20 years of senior management experience with an emphasis in channel sales, business development and marketing. Bob has most recently been the Director of Healthcare for Seneca, a market leader with a wide range of products, engineering and software services. At Intellinetics, Bob will continue to partner with Seneca, working together to jointly develop various strategic partners. Bob was a VP of Sales and Marketing at Optio Software, a leader in Electronic Document Management and Information optimization used in healthcare, government and commercial markets. Bob’s team developed and successfully marketed an Electronic Document Management solution that successfully lowered cost and increased efficiency for hospitals and helped meet HIPPA requirements, JACOH standards and enhanced Electronic Medical Record implementations.

For more information, please visit www.GlobalWiseInvestments.com

Let us hear your thoughts: GlobalWise Investments, Inc. Message Board

Threshold Pharmaceuticals, a biotechnology company, announced today that it has appointed Tillman Pearce, M.D., as its chief medical officer. Dr. Pearce will oversee development of the company’s TH-302, a clinical stage hypoxia-targeted cancer therapeutic currently being evaluated in a variety of cancers. TH-302 is presently undergoing a phase 3 trial in soft tissue sarcoma patients and a phase 2b trial in pancreatic cancer patients.

Dr. Pearce has expertise in oncology drug development – both from the perspectives of large pharmaceutical companies and smaller entrepreneurial biotech companies. His almost two decades of international drug development experience will be valuable to Threshold as the company builds its new partnership with Merck KGaA.

Dr. Pearce’s professional history includes serving as director of oncology clinical research for Sandoz/Novartis, medical director at Sanofi-Synthelabo’s Oncology Business Unit, and founder and director of PDL BioPharma France. Dr. Pearce most recently served as chief medical officer of KaloBios Pharmaceuticals.

Threshold Pharmaceuticals focuses on discovering and developing drugs that target tumor hypoxia, a low oxygen condition found in the microenvironments of most solid tumors and the bone marrows of some hematologic malignancies. This approach offers wide-ranging potential for treating a variety of cancers. By selectively targeting tumor cells, the company is building a pipeline of promising drugs that will more effectively treat cancers with less toxicity to healthy tissues.

For further information about the company, visit www.thresholdpharm.com

Let us hear your thoughts below:

Today, Organic Plant Health, the ingenious provider of a variety of healthy, organic-based products for the care of trees, turf, flowers, gardens, shrubs, and ornamental beds (including fertilizers, soil conditioners, and even disease/insect infestation products), reported on the expansion strategy for the first half of 2012, offering valuable insights to the market as to the company’s action items and goals.

President and CEO of OPHI, Billy Styles, has done a superb job with the Charlotte, NC-based company, already landing the company’s branded products on store shelves in some 25 independent retailers throughout the Carolinas, where a keen market of environmentally conscious Do-It-Yourself homeowners and commercial landscape companies have fallen in love with the offerings.

By late 2011 management finished organizing their tactical strategy via a series of key meetings, readying for the initiation of reporting entity status, which was achieved just last Friday (Feb 10). This is just 14 months after going public and since Friday, management has been working aggressively to implement the defined strategy with utmost efficiency. Among the elements of the OPHI strategy is a more frequent and much more consistent approach to disseminating key updates to shareholders about internal workings of the company.

Styles noted it would be of great importance to assure shareholders via the maintenance of an “open and active line of communication”, as the mandatory 5-month quiet period has generated quite a volume of unanswered buzz. Styles pledged to keep loyal shareholders up to speed and that while every news item may not be earth-shattering, he feels confident that it will create greater overall situational awareness, allowing shareholders to be clued-in to emerging trends and events before they become big news.

Styles emphasized that while dedication to continually increasing shareholder value was paramount, OPHI knows that the core of the business is a community of customers for whom the company will show daily commitment. Styles underlined the significance of the homeowners, gardeners, commercial business, and farmers who have propelled the company to success and reaffirmed that OPHI would continue to show unflagging support for the customers.

By providing accurate, easy to understand protocols, educational materials, videos, and other resources to Americans, Styles is confident that OPHI can not only help to advance sustainability on the cultural level by continuing to provide innovative products, but also by helping to shape the underlying forces. Customers are eager to help create healthier landscapes and a healthier environment, and OPHI will be positioning its products to deliver results.

Additionally, goals for early 2012 include adding on key personnel in the areas of regional and national sales, administrative, marketing, and communications, as well as financial management. All these hires will be done to help crystallize the corporate architecture and allow OPHI to access new revenue streams while expanding existing ones, all with the overarching goal of improved efficiency.

company VP and COO at OPHI, Alan Talbert, echoed his colleagues’ sentiments roundly, adding that the opportunity to expand scope significantly, while getting distribution of the product portfolio really rolling would accelerate momentum in the retail area as hundreds of new retail partners are added in coming months/years.

Talbert noted that while this “full-scale expansion” would not occur overnight, the company is full-throttle and will focus on executing the strategy in a manner consequent with the confidence bestowed by OPHI shareholders over the past 14 months.

For more information on the announcement, or for more information on the company itself, please visit the Organic Plant Health, LLC website at: www.OrganicPlantHealth.com

Let us hear your thoughts below:

L & L Energy announced the conclusion of a management visit to a recently acquired coal mine located in Guizhou Province, China. The visit was led by top officials of the company and also included due diligence inspections on other prospective acquisition opportunities.

In January 2012, L & L Energy announced the acquisition of a 51% interest in the Weishe coal mine for total consideration of $16.2 million. The company issued three million shares of common stock to Union Energy Co. in the deal.

The Weishe coal mine has 19 million tons of coal reserves located in a 1.8 square kilometer section of the property. The mine has a design capacity of 450,000 tons of coal per year.

The visit to the Weishe coal mine was led by Ed Moy and Dr. Syd Pend. Mr. Moy is a Vice President at L & L Energy and Dr. Pend is a member of the company’s board of directors. The two officials reported that the mine was designed with high safety standards and was impressed by the strength of the mine’s management team.

Mr. Moy and Dr. Pend also visited two other coal mines in the area owned by Union Energy Co. and plan to make a future due diligence trip to the facilities.

For more information on the company, go to www.lnlinternational.com

Let us hear your thoughts below:

Wowjoint Holdings is a company on the rise. In a short period of time, the Chinese company has evolved into a leading provider of customized heavy duty lifting and carrying machinery used in large scale infrastructure projects. Today, the company took a major step towards prominence with the announcement they are opening a new manufacturing and R&D facility in Zhenjiang City New District.

The company established a new subsidiary for the property called Zhenjiang Wowjoint Heavy-Duty Machinery Co. Ltd. The new manufacturing facility under Zhengjiang Wowjoint will cover 200,000 square meters of land and is located in Eastern China about 2-3 hours northwest of Shanghai.

In addition, Wowjoint established a new R&D center in Zhenjiang in conjunction with Beijing Jiaoton University’s Yangtze River Delta R&D Transportation Institute in December 2011, which will supply enhanced equipment and services to their customers.

Leading the way at Wowjoint is Mr. Yabin Liu whom serves as the company’s Chief Executive Officer. In reference to this press release, Liu stated, “Wowjoint hopes to expand our market share in China and internationally with our strategic development of the new manufacturing base and new R & D center in Zhenjiang. We believe it’s in a beneficial location close to Shanghai and provides additional resources to capitalize on our international expansion plans.”

Currently, Wowjoint is trading in the $0.61 range. To learn more about this story or the company as a whole, visit their corporate website at: www.wowjoint.com

Let us hear your thoughts below:

Nanosphere, Inc. yesterday announced its financial results for the fourth quarter as well as the full year results of 2011. Revenue and sales were up over the previous year, while operating expenses went down, with an overall reduction in net loss.

Nanosphere manufactures and markets the Verigene System, an advanced molecular diagnostics platform designed for direct genomic and ultra-sensitive protein detection. The company boasts that the system is a cost-effective and easy way to test highly sensitive genomes and proteins.

Nanosphere’s revenues were up by $.5 million for the year, from $2 million to $2.5, while product sales rose from $1.4 million to $2.4 million. Operating expenses fell to $38 million from $43.4 million in 2010, in part by a reduction in legal fees and settlements due to a patent dispute that was settled in 2010.

Net loss during 2011 was reduced to $35.4 million versus $40.6 million during 2010. Net loss in Q4 was reported at $8.6 million, compared to the previous year’s net loss of $7.4 million. Cash flow during Q3 and Q4 2011 was negative $7.6 million, and cash at December 31, 2011, was $39.3 million.

William Moffitt, Nanosphere’s president and CEO, said, “We shipped 30 systems to new customers during the fourth quarter demonstrating an inflection point has been reached in our business. The investments we have made in menu expansion, particularly in the microbiology market segment, have generated significant customer interest and demand.”

Let us hear your thoughts below:

Single Touch Systems, Inc., a technology-based mobile solutions provider serving businesses, advertisers, and brands, today reported financial results for its fiscal first quarter ended December 31, 2011.

Fiscal first-quarter revenue increased 57.1 percent to $1.6 million, compared to revenue of $1.0 million for the same period in 2010. The company attributes the increase in revenue to the launch of new programs and an increase in message volume through retailers; quarterly message volume grew 83 percent compared to the first fiscal quarter of the year prior.

James Orsini, CEO of Single Touch, said the positive trends through the company’s retail channels are driven by retailers acknowledging the efficiency and relevance of mobile marketing.

“As more and more companies recognize the importance of an integrated mobile marketing and communications strategy, Short Message Service (SMS) has emerged as the most intimate and trusted communications channel. Single Touch is well positioned to capitalize on the strength of its highly-scalable technology platform to cost effectively increase both its client base and message volume throughput,” Orsini stated in the press release.

The company reported a 17.9 percent decrease in its loss from operations for the period ended December 31, 2011, excluding stock-based compensation and depreciation and amortization (adjusted EBIDTA) at $0.4 million compared to a loss of $0.5 million in 2010.

Single Touch acknowledged that while adjusted EBITDA is not a measure in accordance with U.S. generally accepted accounting principles (GAAP), the company uses adjusted EBITDA to evaluate the performance of its underlying business:

The net loss (non-GAAP) for the period ended December 31, 2011, was $0.6 million compared to a loss of $4.9 million for the same period last year. The company attributes the improvement to significantly lower stock-based compensation expense of $31,000 incurred during the period, compared to $3.6 million incurred during the same period in 2010.

As of December 31, 2011, Single Touch reports cash and cash equivalents of $1.6 million compared to $0.5 million at the beginning of the period. During the first quarter, the company raised $1.8 million through the issuance of convertible debt. Cash used in operations during the period was $0.6 million. Additionally, the Company invested $0.1 million in CapEx.

For more information visit: www.singletouch.net

Let us hear your thoughts below:

Unemployment filings unexpectedly fell to a four-year low last week, indicating that the labor market could be recovering. Other data from this month show solid expansion in factory activity in the Mid-Atlantic area. In January, builders broke more ground on new residential projects, offering more evidence of a sustained momentum in the economy.

The reports are the latest in a series of fairly upbeat data. Some think that the positive numbers could prompt economists to further temper expectations of a sharp moderation in growth in the first quarter. Similarly, economists have dialed down their expectations for another round of bond-buying or quantitative easing by the Federal Reserve.

“The numbers add to the belief that the economy is shifting gears. There is just no number that is giving us a whole lot of trouble, except for consumer spending,” said Joel Naroff, chief economist at Naroff Economic Advisors in Holland, Pennsylvania.

The Labor Department stated that initial claims for state unemployment benefits dropped 13,000 to a seasonally adjusted 348,000, the lowest level since March 2008. Economists polled by Reuters had forecast claims rising to 365,000. The four-week average of new claims, seen as a better measure of labor market trends, was the lowest since April 2008.

Regarding activity at factories, factories in the region covering eastern Pennsylvania, southern New Jersey and Delaware generally increased hours for existing employees, which usually bodes well for wage growth.

“We are not seeing much indication that growth has slowed from the fourth quarter of 2011 to the first quarter of 2012,” said Gus Faucher, senior economist at PNC Financial Services in Pittsburgh, Pennsylvania.

The Commerce Department reported that housing starts rose 1.5 percent to an annual rate of 699,000 units last month. Economists had predicted a pace of about 675,000 units. Multi-unit buildings boosted the starts, reflecting growing demand for rental apartments as Americans move away from homeownership. Permits for future home construction rose 0.7 percent to a 676,000-unit pace in January. Home building is expected to add to economic growth this year for the first time since 2005.

Let us hear your thoughts below:

Today, Marley Coffee announced new distribution agreements that will expand the artisan roasted gourmet coffee brand’s availability on the U.S. East Coast and in Hawaii. Marley Coffee is now available through NGB Distributing to retailers in Pennsylvania, New Jersey, Delaware, and Maryland.

NGB Distributing, based in Allentown, Pa., services some of the foremost grocery retailers in that region, including Weis Markets, Giant Food Stores, Wegmans, Genuardi’s, Boyer’s Food Markets, Valley Farm, Ahart, Elias Market, and Bottom Dollar, as well as various convenience stores.

Marley Coffee has also increased its presence in Hawaii through a new distribution agreement with Mulvadi Corp., which supplies more than 500 retailers in Hawaii, Guam, Saipan, California, Nevada, China, and Japan. Marley Coffee is additionally available in the region of metropolitan New York through a partnership with leading coffee, water, and food services provider The Evans Company.

Marley Coffee features products that are sustainably grown and ethically farmed. The company presently offers seven varieties of its new Marley Coffee Organic Ground, which is certified USDA organic. The company also produces an assortment of premium Whole Bean Coffee and Single-Serve Pods. All of the Marley Coffee’s products live up to the Rastafari standards of ITAL, which stands for “all things Pure, True and Vital.” A portion of the company’s sales benefit the Kicks for Cause Foundation, which the company founded to build soccer fields and camps for Jamaican children in coffee-producing communities. Marley Coffee is a U.S.-based company that supplies coffee to the grocery, retail, online, service, hospitality, office coffee service, and big box store industries.

For further information about the company, visit www.MarleyCoffee.com

Let us hear your thoughts below:

NeoGenomics, a high-complexity CLIA–certified clinical laboratory specializing in cancer genetics diagnostic testing, today reported its results for the fourth quarter and full year 2011.

“We are very pleased with our Quarter 4 results. For the third quarter in a row we posted the largest year-over-year and sequential quarterly increases in revenue in our corporate history, and our revenue growth rate continued to accelerate throughout the quarter,” Douglas M. VanOort, the company’s chairman and CEO stated in the press release. “Our sales teams were also more productive, as we achieved excellent revenue growth while keeping sales and marketing costs essentially unchanged from Quarter 4 last year. The improved operating leverage from our SG&A expenses allowed us to return to profitability.”

The company posted fourth-quarter revenue at $12.9 million, up 47 percent compared to fourth-quarter revenue of $8.8 million reported for 2010.

Net income for the 2011 fourth quarter was $152,000, or $0.00 per share, compared to a net loss of $377,000 or ($0.01) per share, reported for the fourth quarter of last year. Adjusted EBITDA increased by more than $1.0 million to $1.1 million from $29,000 last year.

For the full year 2011, NeoGenomics reported revenue of $43.5 million, a 27 percent increase over 2010 revenue of $34.4 million.

The company reported a 2011 net loss of $1.2 million or ($0.03) per share, compared to a net loss of $3.3 million or ($0.09) per share in 2010. Adjusted EBITDA for the year increased by $2.7 million to $2.1 million from a loss of $566,000 reported in 2010.

“Our performance improved steadily throughout the year with revenue growth rates and gross margin increasing sequentially in each of the four quarters of 2011,” VanOort continued. “Although average revenue per test declined in 2011, we were able to offset most of that impact with increases in productivity. We also maintained tight cost control throughout 2011. SG&A expense for the full year increased only slightly from 2010, and nearly half of the increase was for normal bad debt expense associated with the strong increase in revenue.”

The Company expects revenue between $54 million – $59 million and net income of $0.02 – $0.04 per share for 2012. For the fiscal first quarter, NeoGenomics said it expects revenue of $13.5 million – $14.0 million and net income of $0.00 to $0.01 per share.

“We believe we are well positioned for continued success. Our current sales pipeline is healthy, and we plan to launch several new sales and marketing initiatives to expand our strategic partnerships with large clients. We also expect a stable reimbursement environment this year, which should allow us to make further improvements in gross margin and profitability. In addition, we plan to significantly expand our molecular and immunohistochemistry test menus, launch the second test under our agreement with Abbott Molecular, and make important investments to begin developing the technology and tests we licensed from Health Discovery Corp,” VanOort stated.

For more information visit www.neogenomics.com

Let us hear your thoughts below:

China Health Resource, a developer and provider of raw and pharmaceutical TCM products, today announced unaudited financial results for the fourth quarter and year ended December 31, 2011.

The company expects 2011 fourth-quarter operating revenues of more than $12.5 million, a 218 percent increase compared to the fourth quarter of 2010. For full year 2011, the company expects operating revenues of $34.9 million, a 241 percent increase over 2010 revenues.

China Health expects 2011 fourth-quarter net income to be $2.7 million, or $0.015 per fully diluted common share, compared with $1.6 million or $0.01 per share, reported for the fourth quarter of 2010. For full year 2011, the company anticipates net income of $6.8 million, or $0.038 per fully diluted common share, compared with a net income of$2.7 million, or $0.02 per share in the year prior.

The company attributes its growth to the expansion of its TCM product lines, improvements in sales channel management to extend market reach, and consistent cost controls.

China Health also provided guidance for 2012 with a focus on growing its product lines and implementing further growth initiatives.

The company anticipates 2012 earnings in the range of $0.06 and $0.065 per share.

Jiayin Wang, President and CEO of CHRI, stated, “Speaking to the company’s focus in 2012, we will continue to maintain our leadership in our DAR franchise while we grow our product lines with valuable and high growth products like Gastrodiae. In addition, we will pursue growth opportunities worldwide through acquisition and distribution and grow in areas where we can best serve customers and create value.”

China Health said it will provide detailed results in its final 2011 fourth quarter and year-end earnings press release and 10-K filing.

For more information visit www.chinahealthresource.com

Let us hear your thoughts below:

Ambient Corp. is a leading provider of smart grid communications platforms and applications to utilities. The company designs, develops, and sells Ambient Smart Grid products and services which include communications nodes, a network management system, AmbientNMS integrated applications, and maintenance and consulting services.

The company today reported financial results for the year ended December 31, 2011. Total revenue for 2011 was $62.3 million, a 206% increase from $20.4 million in 2010. Net income came in at $4.8 million, or 28 cents per diluted share, compared to a net loss of 21 cents a share last year. Ambient’s gross margin increased somewhat too, from 41% last year to 43% in 2011. Finally, its cash position increased to $18 million at year-end from $7 million at the end of 2010.

As can be seen from the numbers, Ambient experienced significant growth last year. It also achieved many key operational milestones. For example at the end of 2011, the company had over 75,000 communications nodes deployed in the field communicating with over 700,000 smart grid end devices. The company is partnered with leading companies in the “smart” meter sector like Itron and Badger Meter and is also partnered with leading utility, Duke Energy.

Interest in Ambient’s communications platform continues to grow and the company is pursuing projects with other potential customers. Its president and CEO, John J. Joyce, said, “On the foundation of a strong balance sheet, driven by field-proven technology…we believe we are well positioned to execute on a primary objective for 2012 – the diversification of our customer base.”

For additional information about Ambient, please visit its website at www.ambientcorp.com

Let us hear your thoughts below:

Bio-Path is a biotechnology company that holds a technology with the potential to revolutionize the treatment of cancer and other diseases. That’s because its neutral lipid delivery capability enables the systemic delivery of nucleic acid drugs to diseased cells, and that’s something no other technology can do.

The company was founded based upon technology licensed from The University of Texas M.D. Anderson Cancer Center, technology that Bio-Path intends to turn into real treatments for cancer patients through the application of the necessary capital and expertise. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers. A second liposomal antisense drug candidate is ready for clinical evaluation for lymphoma and solid tumors. Yet another candidate is a liposomal siRNA cancer drug, currently in the final pre-clinical development stage.

Bio-Path’s neutral lipid delivery technology allows for the systemic distribution of nucleic acid drugs throughout the human body with simple intravenous transfusion. Their delivery technology applies to both double-stranded (siRNA) and single-stranded nucleic acid drugs. Small interfering RNAs, or siRNAs, are the molecules that mediate RNA interference and interfere with the process of producing proteins inside cells. The siRNA are short double-stranded nucleic acid molecules that can be synthesized chemically and introduced into cells, opening doors for the use of siRNAs as drug candidates to treat major diseases such as cancer. Introduction of a double-stranded nucleic acid molecule specific to a target disease-causing protein conditions cellular machinery to shut-down production of that target protein.

Up to now, the biggest challenge facing successful deployment of siRNA drugs has been the lack of a technology that can deliver the double stranded nucleic acid siRNA molecules to the target diseased cells. Bio-Path’s patented delivery technology solves this problem.

For additional information, visit the company’s website at www.BioPathHoldings.com

Let us hear your thoughts below:

MMRGlobal, Inc. announced that leading Southern California outpatient general surgery center Spalding Surgical Center of Beverly Hills is going paperless with MMRPro, MMR’s document management and imaging system. MMRPro is a health IT system designed for hospitals, doctors’ offices, and other healthcare facilities to help lessen rising healthcare costs, improve efficiency, and allow doctors and patients to electronically track results and wellness progress.

Increased use of digitization is rendering pen-and-paper recordkeeping more and more obsolete, and MMRPro is designed to let physicians convert to computerized records without greatly altering the look and feel of a practice’s operations. So far, MMRPro has improved staff productivity at Spalding, enabling office and staff personnel to process information much more quickly and store patient records online more easily – leaving more time and attention for patient care.

MMR will exhibit its suite of health IT products, including a demonstration of MMRPro and its capabilities to transform healthcare facilities into paperless offices with or without a full-featured EMR, at the HIMSS Conference and Exhibition, Feb. 20-24 in Las Vegas. During the conference, MMR will also launch phase 2 of its MMR Stimulus Program, which allows MMR Stimulus Program participation for hospitals that are using selected EMR systems to integrate the MMRPatientView patient portal as a standalone module.

MMRGlobal, Inc. is leading provider of Personal Health Records (PHRs) and electronic document managing and imaging systems designed for professionals in the healthcare field. The company provides secure and user-friendly online PHRs and electronic safe deposit box storage solutions through its wholly owned operating subsidiary MyMedicalRecords, Inc., serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups.

Utilizing proprietary, patented technologies, MyMedicalRecords allows transmission and storage of documents, images, and voicemail messages using various methods, including fax, phone, and file upload; this is accomplished without reliance on any specific electronic medical record platform to populate a user’s account. As an independent software vendor partner with Kodak, MMR delivers an integrated turnkey EMR solution for healthcare professionals.

For further information about the company, visit www.mmrglobal.com

Let us hear your thoughts below:

AUXILIO is a brilliant company with a strong lead as a true pioneer in Managed Print Services (MPS), specifically for the healthcare industry. With a solid focus on the true bottom line, client retention, AUXO boasts an impressive 100% retention rate among hospital partnerships, thanks in large part to the company’s rigorousness in the ferreting out of hidden costs and MPS process inefficiencies.

With print volume reduction programs and key Centers of Excellence, staffed with professional print strategy consultants to devise unparalleled solutions for the requirements of each individual client, the company’s laser-focus on nurturing client caregiver efficiency is only made all the bolder by a continuing commitment to the environment through eco-friendly/e-waste initiatives.

A streamlined and integrated approach to managing/monitoring vital processes in copy, print, and scan infrastructures is provided when AUXILIO steps in. The complex landscape of requirements is solved and the company’s team of experts goes to work; individual hospital units control the purchase and lease of hardware, IT/material management personnel handle supplies, while clinical units handle testing of CAT and MRI functionality/output. The result is a streamline “best use system” that solves the difficult cost equation for profit and usability.

The remarkable cost efficiencies AUXO is able to produce are the result of a firm, hands-on approach developed by the company during its rise to prominence. Indeed, the hallmark of excellence for which AUXO is most widely known is this keen ability to bring high-resolution transparency to the entire spectrum of staff productivity.

As a standard bearer within the industry for cost containment, vendor management, and process refinement, the company strives to apply its well-developed business model, working hand-in-hand with hospital executives to obtain the optimum cost containment envelope for a given operation. There are no upfront fees or unseen risks down the line, only predictable costs and real consistency ensuring the quality of end-user experiences/overall quality of patient care.

Recently, AUXO has seen enthusiasm from the industry in the form of major deals like the recent $40M, five-year contract with Catholic Health East (CHE) to roll out its impressive MPS solutions across 19 CHE facilities. An announcement which quickly followed the $5M, five-year, Memorial Health System (Colorado Springs, CO) agreement from the day before.

The reputation amassed thus far speaks volumes, as healthcare providers turn to AUXO to help shore up costs, confident in the company’s ability to provide intelligent MPS solutions within a risk-free environment where savings are guaranteed. Assuming all print business environment costs via its highly adaptive, customized service integration platform, AUXO is able to stabilize rates at fixed levels unmatched in the industry. As the company continues to innovate, the clients in AUXO’s portfolio of some 1,300 or more U.S. hospitals will continue to benefit.

For more information on this company, or to stay up to date on the latest news and information, please visit AUXILIO’s website at: www.AuxilioInc.com

Let us hear your thoughts below:

Mexco Energy reported its financial results for the third quarter of fiscal 2012 as well as an operational update on the company’s oil and gas activity in the United States. The company is active mostly in Texas, but also has interests in properties in 11 other states.

Mexco Energy reported sales of $757,560 in the quarter ending December 31, 2011, up marginally from the $756,576 reported in the corresponding quarter of fiscal 2011. The company reported net income of $50,961 in the most recent quarter, compared to net income of $26,898 in the third quarter of fiscal 2011.

Mexco Energy attributed the higher net income to an increase in realized prices for sales of natural gas, and an increase in production of crude oil. The company reported an average sales price of $6.10 per Mcfe in the third quarter of fiscal 2012, compared to $5.34 per Mcfe last year. Mexco Energy also reported a 13% increase in the production of crude oil on a year over year basis.

Mexco Energy participated in the drilling of three wells in Texas at the Fuhrman-Mascho Field. The company targeted the Grayburg and San Andres formations on its acreage and currently has interests in seven producing wells in that field.

For more information on the company, go to www.mexcoenergy.com

Let us hear your thoughts below:

Yucheng Technologies, a leading provider of IT solutions to the financial services industry in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2011, reflecting better-than-expected revenue growth for 2011.

The company reported fourth quarter 2011 total revenues of $29.6 million, an increase of 35.1 percent year-over-year and an increase of 55.1 percent sequentially. Total revenues for full year 2011 were $77.1 million, an increase of 26.5 percent year-over-year.

Gross margin for the fourth quarter of 2011 was 42.8 percent, compared to 50.7 percent in the prior year period and 49.7 percent in the previous quarter. Gross margin in 2011 was 47.0 percent, compared to 48.8 percent in 2010.

Fourth quarter 2011 net income was $3.5 million, or $0.17 per diluted share, compared to a net loss of $1.6 million, or $(0.08) per diluted share in the prior year period. The company reported full year 2011 net income of $7.1 million, or $0.36 per diluted share, compared to $0.3 million, or $0.02 per diluted share in 2010.

As of December 31, 2011, Yucheng reported cash and cash equivalents and restricted cash totaling $32.5 million, compared to $18.7 million as of September 30, 2011, and $24.5 million as of December 31, 2010.

Operating cash flow in 2011 was a net inflow of $6.6 million.

“We concluded the fiscal year 2011 with another quarter of solid results. We achieved better revenue growth in 2011 than we originally forecasted at the beginning of the year. Looking back over the past two years, we have made steady improvements in management of our operations and turned the company towards positive growth, which is demonstrated by the excellent execution of our operations for eight consecutive quarters,” Weidong Hong, CEO of Yucheng stated in the press release. “Building upon the No. 1 position in the industry, we are committed to further improving our operations and expanding the market share. We look forward to continuing the quarter over quarter of excellent execution to deliver solid and sustainable financial results.”

For more information visit www.yuchengtech.com

Let us hear your thoughts below:

Applied DNA Sciences, marketer of DNA security solutions to protect products, brands, and intellectual property from counterfeit and diversion, today announced its financial results for the fiscal first quarter ended December 31, 2011.

The company reported revenues of $516,904 for the quarter ended December 31, 2011, compared to revenues of $317,817 reported for the comparable quarter ended December 31, 2010.

The company attributes the 63 percent increase in revenues to sales of its SigNature DNA and BioMaterial GenoTyping products. It also notes a 40 percent increase in its customer base for 2011.

First-quarter revenues for the fiscal year represent an 84 percent increase compared to revenues of $280, 678 reported for the fourth quarter ended September 30, 2011.

Applied DNA reported an increase in research and development expenses to $78,473 for the fiscal first quarter, compared to $20,706 for the comparable three months ended December 31, 2010.

Total operating expenses increased to $2.3 million for the three months ended December 31, 2011, compared to $1.4 million reported for the three months ended December 31, 2010.

Net loss for the three months ended December 31, 2011, increased to $2.4 million, compared to a net loss of $1.3 million comparable three months ended December 31, 2010.

For more information visit www.adnas.com

Let us hear your thoughts below: